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Abstract
Background: We compared clinical outcomes among HIV-infected participants receiving ART who were
randomized to viral load (VL) and CD4 cell count monitoring in comparison to CD4 cell count monitoring alone in
Tororo, Uganda.
Methods: Beginning in May 2003, participants with CD4 cell counts <250 cells/μL or WHO stage 3 or 4 disease
were randomized to clinical monitoring alone, clinical monitoring plus quarterly CD4 cell counts (CD4-only); or
clinical monitoring, quarterly CD4 cell counts and quarterly VL testing (CD4-VL). In 2007, individuals in clinical
monitoring arm were re-randomized to the other two arms and all participants were followed until March 31, 2009.
We used Cox Proportional Hazard models to determine if study arm was independently associated with the
development of opportunistic infections (OIs) or death.
Results: We randomized 1211 participants to the three original study arms and 331 surviving participants in the
clinical monitoring arm were re-randomized to the CD4-VL and CD4 only arms. At enrolment the median age was
38 years and the median CD4 cell count was 134 cells/μL. Over a median of 5.2 years of follow-up, 37 deaths and
35 new OIs occurred in the VL-CD4 arm patients, 39 deaths and 42 new OIs occurred in CD4-only patients. We did
not observe an association between monitoring arm and new OIs or death (AHR =1.19 for CD4-only vs. CD4-VL;
95 % CI 0.82–1.73).
Conclusion: We found no differences in clinical outcomes associated with the addition of quarterly VL monitoring
to quarterly CD4 cell count monitoring.
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Background
One of the greatest global public health achievements
has been the rapid scaling up of antiretroviral therapy
(ART) in resource limited settings over the past decade.
This has largely been achieved through the “public
health approach” promoted by the World Health
Organization (WHO) [1–3]. This approach has involved
training a range of different health-care personnel to
support delivery and monitoring of ART treatment and
care services with the aim of shifting from a centralized,
doctor-led model of HIV treatment and care to decen-
tralized models, thus enabling a larger number of people
to be initiated and retained in care [3, 4].
The WHO 2003 guidelines for the use of ART initially
did not recommend viral load (VL) testing as a necessary
component of treatment programs. However, the WHO
2013 guidelines now recommend VL testing as the pre-
ferred monitoring approach to diagnose and confirm
ART treatment failure in both adults and children. Thus
many countries such as Uganda [5] have revised their
national guidelines for the provision of ART to recom-
mend VL monitoring as the preferred standard. How-
ever, VL testing remains relatively costly and more
technologically challenging in comparison to clinical or
CD4 cell count monitoring in resource limited settings.
Moreover, the WHO scale-up strategy is based on
decentralized, integrated delivery of HIV care. However,
in rural areas where most patients live, local health fa-
cilities generally do not have access to sophisticated la-
boratories and referral networks for transporting
samples to, and receiving results from, centralized la-
boratories [1, 6]. While there are advantages to provid-
ing access to VL testing such as earlier detection of
treatment failure and thus a reduced likelihood of
developing ART drug resistance, this approach is still
debated in resource limited settings [7–11].
The Home-Based AIDS Care (HBAC) project was a 3
arm clinical trial which found that clinical monitoring
alone resulted in increased risk of new OIs or death, in
comparison to the two other arms where routine labora-
tory monitoring was available [8]. However, the study
found no difference in clinical outcomes between partic-
ipants who were randomized to VL and CD4 cell count
monitoring in comparison to CD4 cell count monitor-
ing, alone after 3 years of follow-up. The only other ran-
domized trial which has directly compared clinical
outcomes between patients monitored with VL and CD4
cell counts with those monitored with CD4 cell counts
alone, conducted in Thailand found similar results. [12]
In, 2007, following the end of the first phase of the
HBAC trial, participants who were originally randomized
to the clinical monitoring arm were re-randomized to ei-
ther the VL or the CD4 cell count monitoring arm and
all participants were observed for an additional 2 years
of follow-up. We now report on the long term clinical
outcomes from this study with this additional follow-up
time. The objective of this continuation of the HBAC
trial was to see if any additional differences emerged
with additional follow-up between individuals receiving
CD4 cell count monitoring and VL testing in compari-




Beginning in May, 2003, we assessed for eligibility for
study enrolment of HIV positive adult patients ≥18 years
who had registered with The AIDS Support Organization
(TASO) - Tororo branch. Enrolment was offered to pa-
tients with a CD4 cell count <250 cells/μL or severe HIV
disease (defined as WHO stage 3 or 4 or a history of re-
current herpes zoster). Additional enrollment criteria are
described elsewhere. [8] We obtained written informed
consent from all the study participants that were enrolled
in the study. Participants initiated ART with combinations
of lamuvidine with either niverapine or efavirenz; and zi-
dovudine or stavudine, In April, 2007, following analysis
of the first phase of the study which demonstrated that
clinical follow-up only participants were at increased risk
for death and/or new opportunistic infections (OIs) [8],
these participants were re-randomized to either clinical
monitoring and quarterly CD4 cell counts and VL (CD4-
VL) or clinical monitoring and quarterly CD4 cell counts
only (CD4-only) and all participants were followed until
March 31, 2009. Trained lay field workers continued to
provide ART to participants at home including collecting
data to monitor potential toxicity, morbidity and mortal-
ity. However, the frequency of home visits was changed in
the second phase of the study over a 4 month period from
once per week to once every 2 months. Pre-packaged
drugs were replaced by using a storage container, and pill
counts were conducted at the study clinic by a pharmacist.
Participants were weighed during home visits and these
weights and body mass index (BMI) scores were provided
to clinicians. After enrolment, no routine clinic visits were
scheduled but participants were encouraged to come to
the clinic or hospital if they were ill and were transported
to the clinic for assessment if they had specifically defined
symptoms or severe illness during a home visit.
Monitoring and diagnostic procedures for the occur-
rence of illness did not differ between study arms. Physi-
cians responsible for patients in the two study arms
received laboratory results on a quarterly basis. Partici-
pants received daily cotrimoxazole prophylaxis regardless
of CD4 cell count except during a five-month cotrimoxa-
zole discontinuation sub-study [13] Participants who had
ART treatment failure as per the arm-appropriate defini-
tions below were switched to didanosine, tenofovir, and
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lopinavir/ritonavir. In the CD4-VL arm, treatment failure
was defined as two consecutive viral load measurements
≥500copies/mL occurring more than 6 months after the
start of ART. For the CD4-only arm, persistently declining
CD4 cell counts on two consecutive measurements was
considered to indicate treatment failure. The first response
to a worsening trend in CD4 or VL was counselling about
adherence to treatment. Study physicians, nurses, counsel-
lors, and other staff met weekly in a case conference to
discuss all deaths, opportunistic illnesses, and abnormal
laboratory results and approved all regimen changes. A
data safety monitoring board reviewed data every 3
months and was asked to reject the null hypothesis of
monitoring arm equivalence if the rate of severe morbidity
and mortality in any arm exceeded another by three
standard errors of the difference (“Haybittle-Peto” rule)
[14, 15]. The study received ethics approval from the
University of British Columbia, the UgandaVirus Research
Institute, and the Institutional Review Board of the United
States Center for Disease Control and Prevention and the
Uganda National Council for Science and Technology.
The trial was registered at ClinicalTrials.gov, Registration
number NCT00119093.
Laboratory procedures
HIV VL was measured with Cobas Amplicor HIV-1
Monitor version 1.5 ultrasensitive assay (Roche,
Branchburg, NJ) for baseline measurements, which had
a lower limit of detection of 400 copies/mL. Follow-up
VL measurements were conducted with the Cobas
Taqman (manual extraction) assay, with a lower limit of
detection of 50 copies/mL. CD4 cell counts were done
with Tri TEST reagents following an in house dual plat-
form protocol and MultiSET and Attractors software
with a FAC Scan or FACS Calibur flowcytometer
(Becton-Dickinson, Franklin Lakes, NJ). Complete
blood counts were provided with CD4 cell counts [6].
Data analysis
We followed the study participants randomized or re-
randomized in the remaining two arms for an additional
2 years up to 21st March 2009. We conducted bivariate
analyses of clinical and demographic characteristics of
study participants in the remaining two arms. Data were
analyzed with SAS 9.0 (SAS Institute, Cary,NC). We used
Kaplan-Meier survival curves to graphically compare time
to first opportunistic illness (OI) or death after 90 days fol-
lowing ART initiation (or after re-randomization for those
who were re-randomized to the CD4-VLor CD4-only
arms). Adherence to therapy was calculated using the
medication possession ratio. [16] Cox proportional haz-
ards regression models were used to adjust for possible
confounding, by age, sex, baseline CD4 cell count, VL
and body mass index (BMI). Poisson regression analysis
with log link function was used to compare the rates of
new opportunistic infections and/or deaths occurring
after 90 days following ART initiation (or after re-
randomization for those who were re-randomized). Lo-
gistic regression models were used to compare the
proportions that were switched to second line regimens
and proportion that had elevated (≥500 copies/mL)
viral loads after 6 months on ART or after re-
randomization for those who were re-randomized.
Person time for people lost to follow-up or transferred
to a different provider was censored at the time of the
last home visit at which they received ART.
Results
A total of 1211 participants were randomized beginning
in May 2004 and started on ART in the initial three
study arms (413 in VL arm 411 in CD4 cell count arm
and 387 in the clinical arm [8]. Overall, 71.8 % of the
participants were female, the median age was 38 years
(IQR: 32–44) and the median baseline CD4 cell count
was 134 cells/mL (IQR: 70–199). In April, 2007, 331 sur-
viving participants in the clinical arm were re-
randomized to the VL (165) and CD4 cell count (166)
arms (Fig. 1). Demographic and clinical parameters were
similar across the two study arms, (Table 1).
As of April 30, 2009, the median follow-up time for
all participants was 5.2 years from the original
randomization date and 4.8 years after 90 days on ART
(or re-randomization). During follow-up after 90 days
on ART (or re-randomization) 37 deaths and 35 new
OIs occurred in patients randomized or re-randomized
to the CD4-VL arm and 39 deaths. The last median
CD4 for VL arm was 560, IQR (324–602) while CD4
arm was 554, 1QR (331–595). We did not find any sig-
nificant differences between the two arms p = 0.986.
Forty two (42) new OIs occurred in patients in the CD4
cell count arm. The most common OIs diagnosed
among participants were tuberculosis (49 % of OIs),
followed by Cryptococcosis (13 %), and Kaposi’s
sarcoma (10 %).
In a Kaplan-Meier analysis, we found no difference in
the time to first event of new OI or mortality between
the two monitoring arms (Fig. 2.) rate of 3.0 per 100
person-years in the CD4-VL arm compared to 3.2 per
100 person-years in the CD4 arm; p = 0.605 for log-rank
test. Adherence was similar across the two study arms
with the mean adherence over each visit interval of 99 %
in each study arm (p = 0.123). In a Cox proportional haz-
ards model with adjustment for baseline age, sex, CD4
cell count, viral load, and BMI, there was no statistically
significant difference in the risk of first serious morbidity
or death between the CD4 arm and the CD4-VL arm;
adjusted hazard ratio [AHR] 1.19, 95 % confidence inter-
val 0.82–1.73) for the CD4 cell count arm in comparison
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to the CD4-VL arm. We did not find any statistically sig-
nificant difference between the two arms in terms of
mortality (HR =1.12, 95 % CI: 0.70–1.77) (Table 2) or
the number of severe morbidity events including death
(RR = 1.23, 95 % CI: 0.88–1.71) after adjusting for
baseline age, sex, CD4 cell count, viral load, and BMI
(data not shown), when analyzed separately.
During the follow-up, 182 participants had at least one
elevated VL measurement (≥500 copies/mL after 6 months
or re-randomization for those who were re-randomized;
80 (14.6 %) in the CD4-VL arm, 102 (18.9 %) in the CD4
arm (Table 3). These differences were not statistically sig-
nificant (Odds ratio = 1.31 for CD4 cell count arm relative
to CD4-VL arm, 95 % CI: 0.95–1.83). A total of 54 partici-
pants were changed to a second-line regimen (Table 4), 30
(5.3 %) in the CD4-VL arm, and 24 (4.3 %) in the CD4
arm (Table 4). Again these differences were not statisti-
cally significant) (OR = 0.76) for the CD4 arm compared
to the CD4-VL arm, 95 % CI: 0.44–1.33). Of the 24 indi-
viduals in the CD4 arm who were switched to second-line
therapy, 11(46 %) were found to have had VLs > 500 cop-
ies/mL after 6 months of ART. We noted that a smaller
proportion of patients in the CD4-VL arm who ever had
two VL results ≥500 copies/mL compared to those in the
CD4 monitoring arm (4.6 % vs. 7.5 %). However this dif-
ference was not statistically significant (p = 0.56). At the
close of the study, 92 % of the participants on the CD4
only arm had undetectable viral loads.
Discussion
In this extension of the HBAC study as a two-arm trial,
we found no statistically significant differences in clinical
outcomes associated with the addition of quarterly VL
monitoring to quarterly CD4 cell count monitoring after
over 5 years of follow-up. Furthermore, we did not find
any differences in terms of the proportion of participants
Table 1 Baseline characteristics of HBAC study participants
Tororo and Busia Districts, Uganda, 2003-9, according to type of
monitoring: viral load arm
ALL Viral load arm CD4 arm
Variable N % n % n % p-value
Sex
F 810 72.7 409 73.0 401 72.4 0.807
M 304 27.3 151 27.0 153 27.6
Baseline CD4
<50 197 17.7 97 17.4 100 18.1 0.824
50–200 645 58.1 322 57.7 323 58.5
>200 268 24.1 139 24.9 129 23.4
Baseline viral load
<1000 35 3.2 17 3.1 18 3.3 0.434
1000–9999 47 4.3 28 5.1 19 3.5
10,000–99,999 311 28.3 148 26.8 163 29.9
> = 100,000 705 64.2 360 65.1 345 63.3
Baseline BMI
<18.5 302 27.8 149 27.4 153 28.1 0.347
18.5–24.9 713 65.5 351 64.5 362 66.5
25–29.9 53 4.9 32 5.9 21 3.9
> = 30 20 1.8 12 2.2 8 1.5
Fig. 1 Study profile
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Fig. 2 Kaplan-Meier curves of time to first opportunistic illness or death. a-c Porportion of participants without opportunistic infection/illness/mortality
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with unsuppressed VL or rate of switching to second-line
therapy between these two strategies. Our analysis again
suggests that the addition of VL monitoring to CD4 cell
count monitoring may not result in improved clinical out-
comes for HIV positive patients receiving ART in resource
limited settings. This conclusion is the same as that of the
original HBAC study and the only other direct compari-
son of VL and CD4 cell count monitoring, another RCT
conducted in Thailand [12, 17]. The latter study reported
that a CD4 switching strategy was non-inferior in terms of
clinical outcomes among HIV-positive adults, 3 years after
beginning ART when compared to a VL -based switching
strategy [12]. The authors found that there was also no
difference between the strategies in terms of virologic sup-
pression and immune restoration. Importantly, however,
even though patients in the CD4 arm spent longer with a
high viral load than patients in the VL arm, the emer-
gence of HIV mutants resistant to antiretroviral drugs
was similar in the two arms [12]. Unfortunately, we
do not have any resistance data in order to make
comparisons in this regard.
These findings differ somewhat from the results of an
analysis of mortality of patients on ART in Southern
Africa from the International epidemiological Databases
to Evaluate AIDS in Southern Africa (IeDEA-SA) [8].
Participants from programs which did not have access to
VL testing, namely those in Zambia and Malawi re-
ported higher rates of death and loss to follow up, in
comparison to participants from South Africa where VL
measurement was accessible and readily available. How-
ever, it is unlikely that the only differences between these
programs related to the provision of VL testing and dif-
ferences in health care systems and living environments
of these patients likely also influenced the differences in
outcomes observed. Studies which compared the effect
of routine VL testing to the standard of care where VL
was used sparingly to adjudicate discrepancies between
CD4 and clinical assessments, found that VL monitoring
did not reduce death over the first 36 months of ART
but did result in earlier ART regimen change [8, 9, 18].
A similar exploratory study by AIDS Clinical Trials
Group A5115 that followed up participants for three
Table 2 Cox proportional hazards regression analysis for time to first morbidity (OI) or mortality event
Arm # people # Events Person years Rate per 100 person years Hazard Ratio (95 % CI) a p_value
Original Viral load and CD4 arms
Viral load arm 395 49 1617.3 3.03 ref.
CD4 arm 388 53 1607.7 3.30 1.22( 0.82 to 1.84) 0.327
Re-randomized from Clinical arm
Viral load arm 165 8 313.3 2.55 ref.
CD4 arm 166 9 314.1 2.87 1.14( 0.42 to 3.10) 0.801
All combined
Viral load arm 560 57 1930.6 2.95 ref.
CD4 arm 554 62 1921.9 3.23 1.19( 0.82 to 1.73) 0.368
aAdjusted for Age, sex, baseline CD4, Viral load and BMI
Table 3 Proportion switched to second line regimen (after re-randomization for those who were re-randomized)
Arm # people Number Percent Odds Ratio (95 % CI) a p-value
Original Viral load and CD4 arms
Viral load arm 395 15 3.8 ref.
CD4 arm 388 13 3.4 0.87( 0.40 to 1.90) 0.727
Re-randomized from Clinical arm
Viral load arm 165 15 9.1 ref.
CD4 arm 166 11 6.6 0.70( 0.31 to 1.60) 0.399
All combined
Viral load arm 562 30 5.3 ref.
CD4 arm 557 24 4.3 0.76( 0.44 to 1.33) 0.343
aAdjusted for Age, sex, baseline CD4, Viral load and BMI
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years and compared a treatment switching strategy
based on CD4-only monitoring versus VL thresholds in
21 public hospitals throughout Thailand reported no sig-
nificant differences in activated or total CD4 cells at
study end [19, 20]. Despite the lack of evidence of clin-
ical benefit to support the use of routine VL testing,
there may be other reasons to promote increase use of
VL testing. Routine monitoring of participants with VL
may result in reduction in the time a patient takes a failing
regimen and potentially reducing the frequency of devel-
oping drug resistant mutations [21]. However, to date,
there is very little evidence that the drug resistance muta-
tions which develop while patients are failing their first-
line regimens have much effect on the success second-line
therapy. A study from Malawi found that virologic re-
sponses to a second line regimen among 109 participants
with immunologically-defined treatment failure and a
measured VL ≥1000 copies/mL was quite good (85 % VL
< 400 copies/mL among those with VL measurements at
12 months after switching), although mortality was quite
high at 9 %. All patients in this study had viruses with at
least one resistance mutation, and 56 % of patients had vi-
ruses with thymidine analogue mutations, but the authors
did not find an association with these mutations and viro-
logic suppression at one-year after treatment switching
[22]. Furthermore, the Thai RCT described above, did not
find differences in the accumulation of virologics resist-
ance mutations. More evidence from larger studies are
needed to determine whether virologic monitoring can
improve outcomes for individuals diagnosed with treat-
ment failure in resource-limited settings. In the interim,
designing HIV programmes that maximize retention of
patients in the continuum of care and support adherence
counselling to treatment should remain the focus of HIV
treatment programmes. [23–25] Many programmes in
Sub-Saharan Africa have reported a loss to follow up
among patients on ART of 20 % or more suggesting po-
tential for improvement [26, 27].
This study has a number of limitations; firstly, the
generalizability of our study findings to routine care set-
tings may be limited as participants in this trial were
seen and counseled more frequently than is routine in
most settings. In the first phase of the HBAC study, par-
ticipants received weekly home delivery of ART and clin-
ical monitoring by field officers. However, in this phase
of the study we extended the interval between home
visits to once every 2 months over a 4 month period, in
order to reflect standard care models. The intensity of
the follow-up likely contributed to the low overall rates
of virologic failure and loss to follow-up in comparison
to those reported in most other settings. It is also im-
portant to note that laboratory evaluations were per-
formed every 3 months, rather than every 6 months that
is recommended by WHO. Furthermore, the rates of
virological failure in our study were generally lower than
most reported programmes from the region, as surveyed
in a recent systematic review [27–30].
Conclusions
In conclusion, we found that clinical outcomes in the
first 5 years after ART initiation were not different be-
tween participants with access to CD4 testing alone in
comparison to those with routine VL and CD4 cell
count testing. These data support the continued expan-
sion of access to ART in resource-limited settings, irre-
spective of the availability of VL testing.
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